Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 401–500 of 3,636
Brieger, D. B., Cullen, L., Briffa, T. G., Zaman, S. J., Scott, I. A., Papendick, C., Bardsley, K., Baumann, A. A. W., Bennett, A., Clark, R. A., et al. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.02.102 · Cited by 74
Banach, M., & Penson, P. E. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy301 · Cited by 56
Miname, M. H., & Santos, R. D. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.10.003 · Cited by 61
Advances in treatment of Dyslipidemia
Dybiec, J., Baran, W., Dąbek, B., Fularski, P., Młynarska, E., Radzioch, E., Rysz, J., & Franczyk, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713288 · Cited by 55
“There are also papers suggesting a positive cardiovascular effect in post-acute coronary syndrome patients using statins [52].”
BackgroundMasana, L., Ibarretxe, D., & Plana, N. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01326-w · Cited by 61
Novel Therapeutical Approaches to Managing Atherosclerotic Risk
Giglio, R. V., Stoian, A. P., Al‐Rasadi, K., Banach, M., Patti, A. M., Ciaccio, M., Rizvi, A. A., & Rizzo, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094633 · Cited by 57
Gu, J., Sanchez, R. J., Chauhan, A., Fazio, S., & Wong, N. D. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100336 · Cited by 54
“Since 2014, other novel LLTs that provide powerful LDL-C lowering have come to market, including two proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, which lower LDL-C levels by up to 60% and reduce CV events among patients with ASCVD on statin therapy[3,4,7].”
BackgroundHao, Y., Yang, Y., Wang, Y.-C., & Li, J. (2022) · International Heart Journal · doi:10.1536/ihj.22-052 · Cited by 58
Future perspectives of the pharmacological management of diabetic dyslipidemia
Patti, A. M., Giglio, R. V., Παπάνας, Ν., Rizzo, M., & Rizvi, A. A. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1567328 · Cited by 58
Zhao, Z., Du, S., Shen, S., Luo, P., Ding, S., Wang, G., & Wang, L. (2019) · Medicine · doi:10.1097/md.0000000000014400 · Cited by 67
Milionis, H. J., Ntaios, G., Korompoki, E., Vemmos, K. N., & Michel, P. (2019) · International Journal of Stroke · doi:10.1177/1747493019873594 · Cited by 61
“8 years.(33) This included a significant reduction of ischemic stroke.”
BackgroundIschemic Event Rates in Very-High-Risk Adults
Colantonio, L. D., Shannon, E., Orroth, K. K., Zaha, R. L., Jackson, E. A., Rosenson, R. S., Exter, J., Mues, K. E., & Muntner, P. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.09.025 · Cited by 65
Grundy, S. M., & Stone, N. J. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.0911 · Cited by 58
Contemporary Management of Dyslipidemia
Ferraro, R., Leucker, T. M., Martin, S. S., Banach, M., Jones, S. R., & Toth, P. P. (2022) · Drugs · doi:10.1007/s40265-022-01691-6 · Cited by 66
“The Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment with Alirocumab trial (ODYSSEY OUTCOMES) further demonstrated the efficacy of alirocumab [67].”
BackgroundMethodLee, S., Lee, Y., Heo, J. H., Hur, S., Choi, H. H., Kim, K.-J., Kim, J. H., Park, K. H., Lee, J. H., Choi, Y. J., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.007 · Cited by 60
Klug, E. Q., Llerena, S., Burgess, L. J., Fourie, N., Scott, R. S., Vest, J., Caldwell, K., Kallend, D. G., Stein, E. A., & LIBERATE-HR Investigators (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.1659 · Cited by 67
Management of Familial Hypercholesterolemia: Current Status and Future Perspectives
Lui, D. T. W., Lee, A. C. H., & Tan, K. C. B. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa122 · Cited by 68
Personalized medicine for cardiovascular diseases
Tada, H., Fujino, N., Nomura, A., Nakanishi, C., Hayashi, K., Takamura, M., & Kawashiri, M. (2020) · Journal of Human Genetics · doi:10.1038/s10038-020-0818-7 · Cited by 64
Targeted Therapy in Cardiovascular Disease: A Precision Therapy Era
Xu, M., Zhang, K., & Song, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.623674 · Cited by 61
“As the first PCSK9 inhibitor approved by the Food and Drug Administration (FDA), the alirocumab was used in the ODYSSEY OUTCOMES trial and its effect on cardiovascular mortality after acute coronary syndromes (ACS) was examined (Schwartz et al., 2018).”
BackgroundMethodInfluentialMakhmudova, U., Samadifar, B., Maloku, A., Haxhikadrija, P., Geiling, J.-A., Römer, R., Lauer, B., Möbius-Winkler, S., Otto, S., Schulze, P. C., et al. (2023) · Clinical Research in Cardiology · doi:10.1007/s00392-022-02147-3 · Cited by 52
“ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab (ODYSSEY Outcomes) showed that targeting LDL-C levels to 25–50 mg/dL with alirocumab reduced the number of ACSVD events by 15% in patients with a recent acute coronary syndrome [17].”
PCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives
Nicholls, S. J. (2023) · Kardiologia Polska · doi:10.33963/kp.a2023.0030 · Cited by 60
Alhomoud, I. S., Talasaz, A. H., Mehta, A., Kelly, M. S., Sisson, E. M., Bucheit, J. D., Brown, R., & Dixon, D. L. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2851 · Cited by 63
Dicembrini, I., Giannini, S., Ragghianti, B., Mannucci, E., & Monami, M. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01019-4 · Cited by 51
Preventive Cardiology as a Subspecialty of Cardiovascular Medicine
Shapiro, M. D., Maron, D. J., Morris, P. B., Kosiborod, M., Sandesara, P. B., Virani, S. S., Khera, A., Ballantyne, C. M., Baum, S. J., Sperling, L. S., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.1016 · Cited by 56
Self-citationGuo, Y., Yan, B., Gui, Y., Tang, Z., Tai, S., Zhou, S., & Zheng, X. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30025 · Cited by 62
“PCSK9 inhibitors significantly reduced systemic LDL‐c levels in several large clinical trials, including ODYSSEY (Robinson et al., 2015; Schwartz et al., 2018; Szarek et al., 2019) and FOURIER (further cardiovascular outcomes research with PCSK9 inhibition subjects with elevated risk; Bonaca et…”
BackgroundInfluentialNew Trends in Dyslipidemia Treatment
Jang, A. Y., Lim, S., Jo, S.-H., Han, S. H., & Koh, K. K. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-1037 · Cited by 62
O’Fee, K., Deych, E., Ciani, O., & Brown, D. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.5726 · Cited by 58
Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond
Safarova, M. S., Bimal, T., Soffer, D. E., Hirsh, B. J., Shapiro, M. D., Mintz, G. L., Cha, A., & Gianos, E. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100701 · Cited by 54
Immune-Mediated Inflammatory Diseases, Dyslipidemia, and Cardiovascular Risk: A Complex Interplay
Wilkinson, M. J., & Shapiro, M. D. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.319983 · Cited by 64
Diabetes-Driven Atherosclerosis: Updated Mechanistic Insights and Novel Therapeutic Strategies
Karakasis, P., Theofilis, P., Patoulias, D., Vlachakis, P. K., Antoniadis, A. P., & Fragakis, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052196 · Cited by 71
“The FOURIER and ODYSSEY OUTCOMES trials demonstrated that treatment with the anti-PCSK9 monoclonal antibodies evolocumab and alirocumab significantly improved cardiovascular outcomes compared to placebo [127,128].”
Low LDL cholesterol by PCSK9 variation reduces cardiovascular mortality
Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.517 · Cited by 51
Evison, B. J., Palmer, J. T., Lambert, G. C., Treutlein, H., Zeng, J., Nativel, B., Chemello, K., Zhu, Q. X., Wang, J., Teng, Y., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115344 · Cited by 57
Scicali, R., Pino, A. D., Urbano, F., Ferrara, V., Marchisello, S., Mauro, S. D., Scamporrino, A., Filippello, A., Rabuazzo, A. M., Purrello, F., et al. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.11.009 · Cited by 53
Janik, M. J., Urbach, D. V., van Nieuwenhuizen, E., Zhao, J., Yellin, O., Baccara-Dinet, M. T., Pordy, R., & Manvelian, G. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.06.913 · Cited by 51
Self-citationPrimary prevention of cardiovascular disease: Updated review of contemporary guidance and literature
Stewart, J., Addy, K., Campbell, S., & Wilkinson, P. (2020) · JRSM Cardiovascular Disease · doi:10.1177/2048004020949326 · Cited by 82
Albosta, M. S., Grant, J. K., Taub, P., Blumenthal, R. S., Martin, S. S., & Michos, E. D. (2023) · Vascular Health and Risk Management · doi:10.2147/vhrm.s338424 · Cited by 51
“6% ARR; NNT of 63) in the ODYSSEY Outcomes trial for MACE reduction when added to background statin therapy in patients with ASCVD over a relatively short 2–3 year follow-up.(17,18) Furthermore, there does not appear to be a threshold of LDL-C below which benefits cease to exist.”
Background2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations
Zeitouni, M., Sabouret, P. F., Kernéis, M., Silvain, J., Collet, J., Bruckert, É., & Montalescot, G. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa077 · Cited by 61
Current Options and Future Perspectives in the Treatment of Dyslipidemia
Muscoli, S., Ifrim, M., Russo, M., Candido, F., Sanseviero, A., Milite, M., Luozzo, M. D., Marchei, M., & Sangiorgi, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164716 · Cited by 56
“However, the subsequent FOURIER [17] and ODYSSEY OUTCOMES [16] clinical trials did not reveal a significant difference in the incidence of adverse neurocognitive events between patients treated with a PCSK9i versus placebo.”
InfluentialFeng, Z., Li, X., Tong, W. K., He, Q., Zhu, X. L., Xiang, X., & Tang, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.894685 · Cited by 53
“65) (Karatasakis et al., 2017; Sabatine et al., 2017; Schwartz et al., 2018), a real-world study regarded it as a major reason for treatment interruption (Gurgoze et al.”
BackgroundResultMonomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives
Melnikov, I., Kozlov, S. G., Saburova, O., Avtaeva, Y., Guria, K. G., & Ахнафович, Г. З. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032079 · Cited by 59
Lipid lowering combination therapy: From prevention to atherosclerosis plaque treatment
Masana, L., Plana, N., Andreychuk, N., & Ibarretxe, D. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106738 · Cited by 59
Bosco, G., Di Giacomo Barbagallo, F., Spampinato, S., Lanzafame, L., Di Pino, A., Piro, S., Purrello, F., & Scicali, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062444 · Cited by 50
“Finally, The FOURIER and ODYSSEY-Outcomes studies demonstrated that in subjects with a history of ASCVD evolocumab and alirocumab effectively reduced the risk of cardiovascular events [44,45].”
MethodMorrison, A. M., Sullivan, A. E., & Aday, A. W. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2023.04.004 · Cited by 73
Clinical Updates in Coronary Artery Disease: A Comprehensive Review
Bottardi, A., Prado, G. F. A., Lunardi, M., Fezzi, S., Pesarini, G., Tavella, D., Scarsini, R., & Ribichini, F. L. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164600 · Cited by 68
“Similar results were reported with alirocumab in the ODYSSEY (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial [132].”
ResultMichalopoulou, E., Thymis, J., Lampsas, S., Pavlidis, G., Katogiannis, K., Vlachomitros, D., Katsanaki, E., Kostelli, G., Pililis, S., Pliouta, L., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020428 · Cited by 75
“PCSK9 inhibitors, such as alirocumab and evolocumab, provide additional LDL-C reduction in cases of statin intolerance or inadequate response, and have been shown to significantly reduce cardiovascular events in high-risk populations, as seen in the FOURIER and ODYSSEY trials [88,89] (Table 1).”
Han, Y., Chen, J.-Y., Chopra, V., Zhang, S., Su, G., Ma, C., Huang, Z., Ma, Y., Yao, Z., Yuan, Z., et al. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.10.015 · Cited by 50
Oyama, K., Giugliano, R. P., Tang, M., Bonaca, M. P., Saver, J. L., Murphy, S. A., Ruzza, A., KEECH, A. C., Sever, P., Sabatine, M. S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab604 · Cited by 60
Roe, M. T., Li, Q. H., Bhatt, D. L., Bittner, V., Díaz, R., Goodman, S. G., Harrington, R. A., Jukema, J. W., López-Jaramillo, P. A., Lópes, R. D., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042551 · Cited by 54
Self-citationIdentification of a PCSK9-LDLR disruptor peptide with in vivo function
Brousseau, M. E., Clairmont, K. B., Spraggon, G., Flyer, A. N., Golosov, A. A., Grosche, P., Amin, J., André, J., Burdick, D., Caplan, S. L., et al. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.08.012 · Cited by 52
Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis
Tummala, R., Gupta, M., Devanabanda, A. R., Bandyopadhyay, D., Aronow, W. S., Ray, K. K., Mamas, M. A., & Ghosh, R. K. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2059559 · Cited by 56
Information and consensus document for the detection and management of chronic kidney disease
Maset, R. G., Bover, J., Segura, J., Diezhandino, M. G., del Hoyo, J. C., Escalada, J., Fácila, L., Gamarra, J., García‐Donaire, J. A., Matarin, L. G., et al. (2022) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2022.07.003 · Cited by 82
Freeman, A. M., Raman, S. V., Aggarwal, M., Maron, D. J., Bhatt, D. L., Parwani, P. J., Osborne, J., Earls, J. P., Min, J. K., Bax, J. J., et al. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.10.021 · Cited by 59
Self-citationROS-Induced Endothelial Dysfunction in the Pathogenesis of Atherosclerosis
Yan, R., Zhang, X., Xu, W., Li, J., Sun, Y., Cui, S., Xu, R., Li, W., Jiao, L., & Wang, T. (2024) · Aging and Disease · doi:10.14336/ad.2024.0309 · Cited by 118
Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data
Strilchuk, L. M., Fogacci, F., & Cicero, A. F. G. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1620730 · Cited by 51
Meta‐analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD
Talasaz, A. H., Ho, A. (., Bhatty, F., Koenig, R. A., Dixon, D. L., Baker, W. L., & Van Tassell, B. W. (2021) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2635 · Cited by 48
Berman, A. N., & Blankstein, R. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1175-z · Cited by 55
Mandraffino, G., Scicali, R., Rodríguez‐Carrio, J., Savarino, F., Mamone, F., Scuruchi, M., Cinquegrani, M., Imbalzano, E., Pino, A. D., Piro, S., et al. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.01.015 · Cited by 52
Clinical Pharmacology of Statins: an Update
Ferri, N., & Corsini, A. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00844-w · Cited by 56
Schnell, O., Standl, E., Catrinoiu, D., Itzhak, B., Lalic, N. M., Rahelić, D., Škrha, J., Valensi, P. E., & Ceriello, A. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0822-4 · Cited by 52
“PCSK‐9 inhibition The ODYSSEY OUTCOMES study was designed to assess CV outcomes of alirocumab in 18,924 patients with prior acute coronary syndrome and low-density lipoprotein (LDL) cholesterol levels of at least 70 mg/dL, non-high-density lipoprotein (HDL) cholesterol levels of at least 100 mg/dL or an apolipoprotein…”
BackgroundMethodLow-Density Lipoprotein Cholesterol
Cannon, C. P. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.033 · Cited by 52
mRNA Display Reaches for the Clinic with New PCSK9 Inhibitor
Iskandar, S. E., & Bowers, A. A. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00319 · Cited by 54
Integrated specialty pharmacy yields high PCSK9 inhibitor access and initiation rates
Reynolds, V. W., Chinn, M. E., Jolly, J. A., Kelley, T. N., Peter, M. E., Choi, L., Nwosu, S., Leon, B. G. C., & Zuckerman, A. D. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.01.003 · Cited by 47
Petersen-Uribe, Á., Kremser, M., Rohlfing, A., Castor, T., Kolb, K., Dicenta, V., Emschermann, F., Li, B., Borst, O., Rath, D., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011179 · Cited by 49
“Administration of PCSK9 inhibitors significantly improved quality of life [32] and reduced adverse clinical events and mortality in CAD patients [20,33].”
BackgroundCancer therapy's impact on lipid metabolism: Mechanisms and future avenues
Bhatnagar, R., Dixit, N. M., Yang, E. H., & Sallam, T. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.925816 · Cited by 52
“They have profound LDL-lowering effects that have been shown to reduce cardiovascular events (154, 155).”
BackgroundSchwartz, G. G., Szarek, M. J., Bhatt, D. L., Bittner, V., Bujas‐Bobanovic, M., Díaz, R., Fazio, S., Fras, Z., Goodman, S. G., Harrington, R. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad144 · Cited by 63
“8 years in patients with recent acute coronary syndrome (ACS) who received high-intensity or maximum-tolerated statin treatment.(6,8,9) The trial was designed to maximize the number of patients who achieved a target range of LDL-C 0.”
Self-citationChen, J., Fang, Z., Luo, Q., Wang, X., Warda, M., Das, A., Oldoni, F., & Luo, F. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-023-01993-y · Cited by 47
“Although PCSK9 inhibitors effectively reduce LDL-C levels, they have a limited impact on TG levels, typically reducing LDL-C levels by only approximately 10–20% [56, 57].”
BackgroundOptimizing Management of Stable Angina
Montone, R. A., Rinaldi, R., Niccoli, G., Andò, G., Gragnano, F., Piccolo, R., Pelliccia, F., Moscarella, E., Zimarino, M., Fabris, E., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.015 · Cited by 55
Trankle, C. R., Wohlford, G. F., Buckley, L. F., Kadariya, D., Ravindra, K., Markley, R., Park, T. S., Potere, N., Tassell, B. W. V., & Abbate, A. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000706 · Cited by 50
Banach, M., Bruckert, É., Descamps, O. S., Ellegård, L., Владиславович, Е. М., Föger, B., Fras, Z., Kovanen, P. T., Latkovskis, G., März, W., et al. (2019) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2019.08.023 · Cited by 57
“anti-PCSK9 monoclonal antibodies, have offered the opportunity to further significantly reduce LDL-C levels and cardiovascular events in high CV risk patients already on statin therapy [4,5].”
BackgroundThe 2018 AHA/ACC/Multi-Society Cholesterol guidelines: Looking at past, present and future
Stone, N. J., & Grundy, S. M. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.11.005 · Cited by 52
Duffy, E. Y., Ashen, M. D., Blumenthal, R. S., Davis, D. M., Gulati, M., Blaha, M. J., Michos, E. D., Nasir, K., & Cainzos‐Achirica, M. (2021) · Clinical Cardiology · doi:10.1002/clc.23555 · Cited by 58
Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice
Schuster, S., Rubil, S., Endres, M., Princen, H. M. G., Boeckel, J., Winter, K., Werner, C. M., & Laufs, U. (2019) · Scientific Reports · doi:10.1038/s41598-019-47242-0 · Cited by 52
Kalra, D. K., Vijayaraghavan, K., Sikand, G., Desai, N. R., Joshi, P. H., Mehta, A., Karmally, W., Vani, A. K., Sitafalwalla, S. J., Puri, R., et al. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.03.007 · Cited by 50
Wu, Z., Huang, Z., Lichtenstein, A. H., Liu, Y., Chen, S., Jin, Y., Na, M., Bao, L., Wu, S., & Gao, X. (2021) · BMC Medicine · doi:10.1186/s12916-021-02014-4 · Cited by 50
Nishikido, T. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01752-4 · Cited by 46
Statins and diabetes: What are the connections?
Sattar, N. A. (2023) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2023.101749 · Cited by 57
Diabetes and coronary artery disease: not just a risk factor
Grant, P. J., Cosentino, F., & Marx, N. (2020) · Heart · doi:10.1136/heartjnl-2019-316243 · Cited by 47
Yang, Q., Sun, D., Pei, C., Zeng, Y. H., Wang, Z., Li, Z., Hao, Y., Song, X., Li, Y., Liu, G., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab418 · Cited by 45
Arnold, N., & Köenig, W. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01782-6 · Cited by 52
Brunham, L. R., Lonn, E., & Mehta, S. R. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.04.017 · Cited by 60
Gene therapy and genome editing for lipoprotein disorders
Gurevitz, C., Bajaj, A., Khera, A. V., Do, R., Schunkert, H., Musunuru, K., & Rosenson, R. S. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf411 · Cited by 51
Proprotein convertase subtilisin/kexin type 9 and lipid metabolism
Spolitu, S., Dai, W., Zadroga, J. A., & Ozcan, L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000601 · Cited by 46
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Schmidt, A. F., Holmes, M. V., Preiss, D., Swerdlow, D. I., Denaxas, S., Fatemifar, G., Faraway, R., Finan, C., Lumbers, R. T., Henry, A., et al. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-1187-z · Cited by 42
Vaccination in Atherosclerosis
Nettersheim, F. S., Vore, L. D., & Winkels, H. (2020) · Cells · doi:10.3390/cells9122560 · Cited by 50
KEECH, A. C., Oyama, K., Sever, P., Tang, M., Murphy, S. A., Hirayama, A., Lu, C., Tay, L., DEEDWANIA, P. C., Siu, C., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-20-1051 · Cited by 48
Oyama, K., Giugliano, R. P., Blazing, M. A., Park, J., Tershakovec, A. M., Sabatine, M. S., Cannon, C. P., & Braunwald, E. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.011 · Cited by 50
Atherogenic Dyslipidemia and Residual Vascular Risk After Stroke or Transient Ischemic Attack
Hoshino, T., Ishizuka, K., Toi, S., Mizuno, T., Nishimura, A., Takahashi, S., Wako, S., & Kitagawa, K. (2021) · Stroke · doi:10.1161/strokeaha.121.034593 · Cited by 49
Ray, K. K., Dhalwani, N. N., Sibartie, M., Bridges, I. M., Ebenbichler, C. F., Filardi, P. P., Villa, G., Vogt, A., & Bruckert, É. (2022) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcac009 · Cited by 47
Bétrisey, S., Haller, M. L., Efthimiou, O., Speierer, A., Giovane, C. D., Moutzouri, E., Blum, M. R., Aujesky, D., Rodondi, N., & Gencer, B. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.030714 · Cited by 49
Ray, K. K., Prato, S. D., Müller‐Wieland, D., Cariou, B., Colhoun, H. M., Tinahones, F. J., Domenger, C., Letierce, A., Mandel, J., Samuel, R., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0951-9 · Cited by 44
Familial Hypercholesterolaemia in 2020: A Leading Tier 1 Genomic Application
Pang, J., SULLIVAN, D. R., Brett, T., Kostner, K., Hare, D. L., & Watts, G. F. (2019) · Heart Lung and Circulation · doi:10.1016/j.hlc.2019.12.002 · Cited by 50
Kukharchuk, V. V., Владиславович, Е. М., Викторович, С. И., Arabidze, G. G., Балахонова, Т. В., Gurevich, V. S., Zelveyan, P. A., Murataliev, T. M., Myrzakhmetova, G., Александровна, С. О., et al. (2020) · Eurasian heart journal · doi:10.38109/2225-1685-2020-2-6-29 · Cited by 51
Liu, D., Richardson, G. D., Benli, F. M., Park, C., de Souza, J. V. B., Bronowska, A. K., & Spyridopoulos, I. (2020) · Clinical Science · doi:10.1042/cs20191213 · Cited by 50
Sinning, D., & Landmesser, U. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01427-6 · Cited by 44
di Mauro, G., Zinzi, A., Scavone, C., Mascolo, A., Gaio, M., Sportiello, L., Ferrajolo, C., Rafaniello, C., Rossi, F., & Capuano, A. (2020) · Drug Safety · doi:10.1007/s40264-020-01021-3 · Cited by 49
A Critical Review of the Efficacy and Safety of Inclisiran
Hardy, J., Niman, S., Pereira, E., Lewis, T., Reid, J., Choksi, R., & Goldfaden, R. F. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00477-7 · Cited by 44
“Evolocumab and alirocumab are monoclonal antibodies that target PCSK9 with high specificity, preventing degradation of the LDLRs, and studies showed that both agents reduced cardiovascular risk in high-risk patients [10, 11].”
BackgroundResultInclisiran in lipid management: A Literature overview and future perspectives
Scicchitano, P., Milo, M., Mallamaci, R., Palo, M. D., Caldarola, P., Massari, F., Gabrielli, D., Colivicchi, F., & Ciccone, M. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112227 · Cited by 51
Goodman, S. G., Steg, P. G., Poulouin, Y., Bhatt, D. L., Bittner, V. A., Diaz, R., Garon, G., Harrington, R. A., Jukema, J. W., Manvelian, G., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029216 · Cited by 44
“Several limitations are acknowledged: (1) Patients with prior hemorrhagic stroke were excluded.”
BackgroundSelf-citationYing, Z., Tramper, N., Zhou, E., Boon, M. R., Rensen, P. C. N., & Kooijman, S. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac131 · Cited by 48
Wu, W., Chen, G., Wu, K., Zheng, H., Chen, Y., Wang, X., Huang, Z., Cai, Z., Cai, Z., Chen, Z., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01984-4 · Cited by 46
“Although LDL-C has been a particular focus during the past few decades, recent studies have shown that even after target LDL-C concentrations are achieved through statin therapy, the incidence of recurrence of cardiovascular events is high, which indicates that residual risk remains [6, 7].”
Background
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

